Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 1,231–1,240 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 1231
- Medicine slug
- ponesimod
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
99%
- Numeric value
- 99
- Unit
- %
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5be69660-738c-4db7-b0d4-517aa873dc41 (opens source in a new tab)
Ponesimod label
Version not recorded · Effective date not recorded
Ponesimod is highly bound to plasma proteins (> 99%) and is mainly (78.5%) distributed in the plasma fraction of whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c025ba8-ba51-272e-e063-6294a90ad120 (opens source in a new tab)
Ponesimod label
Version not recorded · Effective date not recorded
Ponesimod is highly bound to plasma proteins (>99%) and is mainly (78.5%) distributed in the plasma fraction of whole blood.
Projected row 1232
- Medicine slug
- ponesimod
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
160 L
- Numeric value
- 160
- Unit
- L
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5be69660-738c-4db7-b0d4-517aa873dc41 (opens source in a new tab)
Ponesimod label
Version not recorded · Effective date not recorded
Distribution Following IV administration in healthy subjects, the steady-state volume of distribution of ponesimod is 160 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c025ba8-ba51-272e-e063-6294a90ad120 (opens source in a new tab)
Ponesimod label
Version not recorded · Effective date not recorded
Distribution Following IV administration in healthy subjects, the steady-state volume of distribution of ponesimod is 160 L.
Projected row 1233
- Medicine slug
- posaconazole
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 32
- Source count
- 23
- Agreement rate
- 1
- Recorded readings
54%
- Numeric value
- 54
- Unit
- %
- Source records
- 23
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 23 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5300d14-219d-4e1e-bfac-b413c40d6e3a (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
The absolute bioavailability of the oral delayed-release tablet is approximately 54% under fasted conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4de6d839-e4bd-405c-83c5-8efc6abd0829 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
The absolute bioavailability of the oral delayed-release tablet is approximately 54% under fasted conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d14ceab-196e-4dc3-8b21-5c4629ada161 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
The absolute bioavailability of the oral delayed-release tablet is approximately 54% under fasted conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b073b082-7b57-4423-8c06-4fd4263d6f84 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
The absolute bioavailability of the oral delayed-release tablet is approximately 54% under fasted conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:548124ce-8050-46a9-967b-ff23dfb18633 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
The absolute bioavailability of the oral delayed-release tablet is approximately 54% under fasted conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e809a31a-09da-46bf-bcaa-f34b7f3b54a3 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
The absolute bioavailability of the oral delayed-release tablet is approximately 54% under fasted conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f795eca-7a03-4c91-9a0e-c1235791b665 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
The absolute bioavailability of the oral delayed-release tablet is approximately 54% under fasted conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9c81d88-8e2c-fa53-e053-6394a90ac5c4 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
The absolute bioavailability of the oral delayed-release tablet is approximately 54% under fasted conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e1e69b8-cf41-47cc-a3ec-1baee55f099a (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
The absolute bioavailability of the oral delayed-release tablet is approximately 54% under fasted conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:94a9b028-a2bc-4f41-884d-2d6c536881fc (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
The absolute bioavailability of the oral delayed-release tablet is approximately 54% under fasted conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0bdf77ae-3639-49c1-b7c7-533f9d073084 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
The absolute bioavailability of the oral delayed-release tablet is approximately 54% under fasted conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de95df83-a495-1900-e053-2995a90abf24 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
The absolute bioavailability of the oral delayed-release tablet is approximately 54% under fasted conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8a26673-261c-4e8e-b1e1-9e23aaf7f285 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
The absolute bioavailability of the oral delayed-release tablet is approximately 54% under fasted conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8412398b-c696-4f12-ba3a-da74dc8dadaf (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
The absolute bioavailability of the oral delayed-release tablet is approximately 54% under fasted conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:573d89eb-05d8-4035-b406-6409f36ab707 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
The absolute bioavailability of the oral delayed-release tablet is approximately 54% under fasted conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42a53b61-be3b-4c69-a3df-d12401dbd0e4 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
The absolute bioavailability of the oral delayed-release tablet is approximately 54% under fasted conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0e8023a-3c82-e455-a57b-ccc0206ad156 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
The absolute bioavailability of the oral delayed-release tablet is approximately 54% under fasted conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e883b495-d7e7-6d58-e053-2a95a90a1cd3 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
The absolute bioavailability of the oral delayed-release tablet is approximately 54% under fasted conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f15fc7d4-04ea-4be5-bfed-9a8bae74591c (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
The absolute bioavailability of the oral delayed-release tablet is approximately 54% under fasted conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e031b632-8e57-4359-87bd-a5da02bdc55f (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
The absolute bioavailability of the oral delayed-release tablet is approximately 54% under fasted conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dfbc636f-d8a7-4232-a6b0-cda49caadc9b (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
The absolute bioavailability of the oral delayed-release tablet is approximately 54% under fasted conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8d8dd03-46b5-bd26-bb27-7ca31d8c3326 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
The absolute bioavailability of the oral delayed-release tablet is approximately 54% under fasted conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d2daba09-f1c2-4764-a567-1291be4892b9 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
The absolute bioavailability of the oral delayed-release tablet is approximately 54% under fasted conditions.
Projected row 1234
- Medicine slug
- posaconazole
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 32
- Source count
- 32
- Agreement rate
- 0.6875
- Recorded readings
3 hours
- Numeric value
- 3
- Unit
- hours
- Source records
- 22
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 22 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c551e121-d5fc-4b35-ba9f-72ce3a314fdc (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
nistered drug plus posaconazole to coadministered drug alone for C max or AUC. † The tablet refers to a non-commercial tablet formulation without polymer. ‡ The mean terminal half-life of midazolam was increased from 3 hours to 7 to 11 hours during coadministration with posaconazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5300d14-219d-4e1e-bfac-b413c40d6e3a (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
atin Acid ↑634% (7.34, 5.82-9.25) Simvastatin ↑ 960% (10.60, 8.63-13.02) Simvastatin Acid ↑ 748% (8.48, 7.04-10.23) Midazolam 0.4-mg single intravenous dose The mean terminal half-life of midazolam was increased from 3 hours to 7 to 11 hours during coadministration with posaconazole. 0.4-mg single intravenous dose 2-mg single oral dose 2-mg single oral dose 200 mg (oral suspension) twice daily × 7
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4de6d839-e4bd-405c-83c5-8efc6abd0829 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
nistered drug plus posaconazole to coadministered drug alone for C max or AUC. † The tablet refers to a non-commercial tablet formulation without polymer. ‡ The mean terminal half-life of midazolam was increased from 3 hours to 7 to 11 hours during coadministration with posaconazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86be8cdb-c991-4754-b8f4-1ab79ac40bda (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
nistered drug plus Posaconazole to coadministered drug alone for C max or AUC. † The tablet refers to a non-commercial tablet formulation without polymer. ‡ The mean terminal half-life of midazolam was increased from 3 hours to 7 to 11 hours during coadministration with Posaconazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d14ceab-196e-4dc3-8b21-5c4629ada161 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
atin Acid ↑634% (7.34, 5.82-9.25) Simvastatin ↑ 960% (10.60, 8.63-13.02) Simvastatin Acid ↑ 748% (8.48, 7.04-10.23) Midazolam 0.4-mg single intravenous dose The mean terminal half-life of midazolam was increased from 3 hours to 7 to 11 hours during coadministration with posaconazole. 0.4-mg single intravenous dose 2-mg single oral dose 2-mg single oral dose 200 mg (oral suspension) twice daily × 7
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91f89a3b-2479-4d05-9997-7b0cfaa496ec (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
nistered drug plus posaconazole to coadministered drug alone for C max or AUC. † The tablet refers to a non-commercial tablet formulation without polymer. ‡ The mean terminal half-life of midazolam was increased from 3 hours to 7 to 11 hours during coadministration with posaconazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e809a31a-09da-46bf-bcaa-f34b7f3b54a3 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
↑ 851% (9.51, 8.15 to11.10) Simvastatin ↑ 960% (10.60, 8.63 to 13.02) Simvastatin Acid ↑ 748% (8.48, 7.04 to 10.23) Midazolam 0.4-mg single intravenous dose The mean terminal half-life of midazolam was increased from 3 hours to 7 to 11 hours during coadministration with posaconazole 200 mg (oral suspension) twice daily x 7 days ↑ 30% (1.3; 1.13 to 1.48) ↑ 362% (4.62; 4.02 to 5.3) 0.4-mg single int
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f795eca-7a03-4c91-9a0e-c1235791b665 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
istered drug plus posaconazole to co-administered drug alone for C max or AUC. † The tablet refers to a non-commercial tablet formulation without polymer. ‡ The mean terminal half-life of midazolam was increased from 3 hours to 7 to 11 hours during co-administration with posaconazole . 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Posaconazole is an azole antifungal agent [see Clinical Pharmac
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9c81d88-8e2c-fa53-e053-6394a90ac5c4 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
istered drug plus posaconazole to co-administered drug alone for C max or AUC. † The tablet refers to a non-commercial tablet formulation without polymer. ‡ The mean terminal half-life of midazolam was increased from 3 hours to 7 to 11 hours during co-administration with posaconazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2ba0343-cd17-4b23-8356-005a1dfd0b35 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
nistered drug plus posaconazole to coadministered drug alone for C max or AUC. † The tablet refers to a non-commercial tablet formulation without polymer. ‡ The mean terminal half-life of midazolam was increased from 3 hours to 7 to 11 hours during coadministration with posaconazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:94a9b028-a2bc-4f41-884d-2d6c536881fc (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
inistered drug plus posaconazole to coadministered drug alone for Cmax or AUC. † The tablet refers to a non-commercial tablet formulation without polymer. ‡ The mean terminal half-life of midazolam was increased from 3 hours to 7 to 11 hours during coadministration with posaconazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0bdf77ae-3639-49c1-b7c7-533f9d073084 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
nistered drug plus posaconazole to coadministered drug alone for C max or AUC. † The tablet refers to a non-commercial tablet formulation without polymer. ‡ The mean terminal half-life of midazolam was increased from 3 hours to 7 to 11 hours during coadministration with posaconazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de95df83-a495-1900-e053-2995a90abf24 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
nistered drug plus posaconazole to coadministered drug alone for C max or AUC. † The tablet refers to a non-commercial tablet formulation without polymer. ‡ The mean terminal half-life of midazolam was increased from 3 hours to 7 to 11 hours during coadministration with posaconazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8412398b-c696-4f12-ba3a-da74dc8dadaf (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
tin Acid ↑634% (7.34, 5.82-9.25) Simvastatin ↑ 960% (10.60, 8.63- 13.02) Simvastatin Acid ↑ 748% (8.48, 7.04-10.23) Midazolam 0.4-mg single intravenous dose The mean terminal half-life of midazolam was increased from 3 hours to 7 to 11 hours during coadministration with posaconazole delayed-release tablets. 0.4-mg single intravenous dose 2-mg single oral dose 2-mg single oral dose 200 mg (oral sus
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e88e379-b712-4dec-97a2-c90ef3638372 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
nistered drug plus posaconazole to coadministered drug alone for C max or AUC. † The tablet refers to a non-commercial tablet formulation without polymer. ‡ The mean terminal half-life of midazolam was increased from 3 hours to 7 to 11 hours during coadministration with posaconazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:573d89eb-05d8-4035-b406-6409f36ab707 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
nistered drug plus posaconazole to coadministered drug alone for C max or AUC. † The tablet refers to a non-commercial tablet formulation without polymer. ‡ The mean terminal half-life of midazolam was increased from 3 hours to 7 to 11 hours during coadministration with posaconazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42a53b61-be3b-4c69-a3df-d12401dbd0e4 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
atin Acid ↑634% (7.34, 5.82-9.25) Simvastatin ↑ 960% (10.60, 8.63-13.02) Simvastatin Acid ↑ 748% (8.48, 7.04-10.23) Midazolam 0.4-mg single intravenous dose The mean terminal half-life of midazolam was increased from 3 hours to 7 to 11 hours during coadministration with posaconazole. 0.4-mg single intravenous dose 2-mg single oral dose 2-mg single oral dose 200 mg (oral suspension) twice daily × 7
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e883b495-d7e7-6d58-e053-2a95a90a1cd3 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
tatin Acid ↑851% (9.51, 8.15-11.10) Simvastatin ↑960% (10.60, 8.63-13.02) Simvastatin Acid ↑748% (8.48, 7.04-10.23) Midazolam 0.4-mg single intravenous dose The mean terminal half-life of midazolam was increased from 3 hours to 7 to 11 hours during coadministration with posaconazole. 200 mg (Noxafil ® Oral Suspension) twice daily × 7 days ↑30% (1.3; 1.13-1.48) ↑362% (4.62; 4.02-5.3) 0.4-mg single
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f15fc7d4-04ea-4be5-bfed-9a8bae74591c (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
atin Acid ↑634% (7.34, 5.82-9.25) Simvastatin ↑ 960% (10.60, 8.63-13.02) Simvastatin Acid ↑ 748% (8.48, 7.04-10.23) Midazolam 0.4-mg single intravenous dose The mean terminal half-life of midazolam was increased from 3 hours to 7 to 11 hours during coadministration with posaconazole. 0.4-mg single intravenous dose 2-mg single oral dose 2-mg single oral dose 200 mg (oral suspension) twice daily × 7
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dfbc636f-d8a7-4232-a6b0-cda49caadc9b (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
↑851% (9.51, 8.15 to 11.10) Simvastatin ↑ 960% (10.60, 8.63 to 13.02) Simvastatin Acid ↑748% (8.48, 7.04 to 10.23) Midazolam 0.4-mg single intravenous dose The mean terminal half-life of midazolam was increased from 3 hours to 7 to 11 hours during coadministration with posaconazole. 200 mg (oral suspension) BID × 7 days ↑ 30% (1.3; 1.13 to 1.48) ↑ 362% (4.62; 4.02 to 5.3) 0.4-mg single intravenou
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4032672e-1bb0-427d-a3b3-09cda4beaf34 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
nistered drug plus posaconazole to coadministered drug alone for C max or AUC. † The tablet refers to a non-commercial tablet formulation without polymer. ‡ The mean terminal half-life of midazolam was increased from 3 hours to 7 to 11 hours during coadministration with posaconazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d2daba09-f1c2-4764-a567-1291be4892b9 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
atin Acid ↑634% (7.34, 5.82-9.25) Simvastatin ↑ 960% (10.60, 8.63-13.02) Simvastatin Acid ↑ 748% (8.48, 7.04-10.23) Midazolam 0.4-mg single intravenous dose The mean terminal half-life of midazolam was increased from 3 hours to 7 to 11 hours during coadministration with posaconazole. 0.4-mg single intravenous dose 2-mg single oral dose 2-mg single oral dose 200 mg (oral suspension) twice daily × 7
26 to 31 hours
- Numeric value
- 26
- Unit
- hours
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:548124ce-8050-46a9-967b-ff23dfb18633 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole delayed-release tablet is eliminated with a mean half-life (t½) ranging between 26 to 31 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e1e69b8-cf41-47cc-a3ec-1baee55f099a (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole delayed-release tablet is eliminated with a mean half-life (t½) ranging between 26 to 31 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8a26673-261c-4e8e-b1e1-9e23aaf7f285 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole delayed-release tablet is eliminated with a mean half-life (t ½ ) ranging between 26 to 31 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0e8023a-3c82-e455-a57b-ccc0206ad156 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Renal clearance is a minor elimination pathway, with 13% of the radiolabeled dose excreted in urine up to 120 hours (<0.2% of the radiolabeled dose is parent drug).Posaconazole delayed-release tablet is eliminated with a mean half-life (t ½ ) ranging between 26 to 31 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e031b632-8e57-4359-87bd-a5da02bdc55f (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole delayed-release tablet is eliminated with a mean half-life (t ½ ) ranging between 26 to 31 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8d8dd03-46b5-bd26-bb27-7ca31d8c3326 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole delayed-release tablet is eliminated with a mean half-life (t ½ ) ranging between 26 to 31 hours.
27 hours
- Numeric value
- 27
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b073b082-7b57-4423-8c06-4fd4263d6f84 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Noxafil injection is eliminated with a mean terminal half-life (t ½ ) of 27 hours and a total body clearance (CL) of 7.3 L/h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52d9d29e-4a37-4926-aa57-8477f5447b34 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole injection is eliminated with a mean terminal half-life (t½) of 27 hours and a total body clearance (CL) of 7.3 L/h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ebbd88b-547b-4b49-ab73-98094a2d5a79 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Excretion Posaconazole injection is eliminated with a mean terminal half-life (t ½ ) of 27 hours and a total body clearance (CL) of 7.3 L/h.
35 hours
- Numeric value
- 35
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:282ddea7-47d8-44e4-8806-169d7cafa951 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole oral suspension is eliminated with a mean half-life (t ½ ) of 35 hours (range: 20 to 66 hours).
Projected row 1235
- Medicine slug
- posaconazole
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 32
- Source count
- 32
- Agreement rate
- 1
- Recorded readings
98%
- Numeric value
- 98
- Unit
- %
- Source records
- 32
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 32 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c551e121-d5fc-4b35-ba9f-72ce3a314fdc (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole is highly bound to human plasma proteins (>98%), predominantly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5300d14-219d-4e1e-bfac-b413c40d6e3a (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole is highly bound to human plasma proteins (>98%), predominantly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4de6d839-e4bd-405c-83c5-8efc6abd0829 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole is highly bound to human plasma proteins (>98%), predominantly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86be8cdb-c991-4754-b8f4-1ab79ac40bda (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole is highly bound to human plasma proteins (>98%), predominantly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d14ceab-196e-4dc3-8b21-5c4629ada161 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole is highly bound to human plasma proteins (>98%), predominantly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91f89a3b-2479-4d05-9997-7b0cfaa496ec (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole is highly bound to human plasma proteins (>98%), predominantly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b073b082-7b57-4423-8c06-4fd4263d6f84 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole is highly bound to human plasma proteins (>98%), predominantly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:548124ce-8050-46a9-967b-ff23dfb18633 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
CI=Confidence interval * 48.5 g fat † Median (Min, Max) reported for Tmax Distribution: Posaconazole is highly bound to human plasma proteins (>98%), predominantly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e809a31a-09da-46bf-bcaa-f34b7f3b54a3 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole is highly bound to human plasma proteins (>98%), predominantly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f795eca-7a03-4c91-9a0e-c1235791b665 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole is highly bound to human plasma proteins (>98%), predominantly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9c81d88-8e2c-fa53-e053-6394a90ac5c4 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole is highly bound to human plasma proteins (>98%), predominantly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2ba0343-cd17-4b23-8356-005a1dfd0b35 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole is highly bound to human plasma proteins (>98%), predominantly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e1e69b8-cf41-47cc-a3ec-1baee55f099a (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
CI=Confidence interval * 48.5 g fat † Median (Min, Max) reported for Tmax Distribution: Posaconazole is highly bound to human plasma proteins (>98%), predominantly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52d9d29e-4a37-4926-aa57-8477f5447b34 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole is highly bound to human plasma proteins (>98%), predominantly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:94a9b028-a2bc-4f41-884d-2d6c536881fc (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole is highly bound to human plasma proteins (>98%), predominantly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0bdf77ae-3639-49c1-b7c7-533f9d073084 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole is highly bound to human plasma proteins (>98%), predominantly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de95df83-a495-1900-e053-2995a90abf24 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole is highly bound to human plasma proteins (>98%), predominantly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8a26673-261c-4e8e-b1e1-9e23aaf7f285 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole is highly bound to human plasma proteins (>98%), predominantly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8412398b-c696-4f12-ba3a-da74dc8dadaf (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole is highly bound to human plasma proteins (>98%), predominantly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e88e379-b712-4dec-97a2-c90ef3638372 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole is highly bound to human plasma proteins (>98%), predominantly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:573d89eb-05d8-4035-b406-6409f36ab707 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole is highly bound to human plasma proteins (>98%), predominantly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42a53b61-be3b-4c69-a3df-d12401dbd0e4 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole is highly bound to human plasma proteins (>98%), predominantly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:282ddea7-47d8-44e4-8806-169d7cafa951 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole is highly bound to human plasma proteins (>98%), predominantly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ebbd88b-547b-4b49-ab73-98094a2d5a79 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole is highly bound to human plasma proteins (> 98%), predominantly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0e8023a-3c82-e455-a57b-ccc0206ad156 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole is highly bound to human plasma proteins (>98%), predominantly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e883b495-d7e7-6d58-e053-2a95a90a1cd3 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole is highly bound to human plasma proteins (>98%), predominantly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f15fc7d4-04ea-4be5-bfed-9a8bae74591c (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole is highly bound to human plasma proteins (>98%), predominantly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e031b632-8e57-4359-87bd-a5da02bdc55f (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
gle dose either orally with BOOST or via an NG tube with BOOST (n=16) Via NG tube NG = nasogastric ↓19% (0.81; 0.71-0.91) ↓23% (0.77; 0.69-0.86) Distribution: Posaconazole is highly bound to human plasma proteins (>98%), predominantly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dfbc636f-d8a7-4232-a6b0-cda49caadc9b (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole is highly bound to human plasma proteins (>98%), predominantly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8d8dd03-46b5-bd26-bb27-7ca31d8c3326 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole is highly bound to human plasma proteins (>98%), predominantly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4032672e-1bb0-427d-a3b3-09cda4beaf34 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole is highly bound to human plasma proteins (>98%), predominantly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d2daba09-f1c2-4764-a567-1291be4892b9 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Posaconazole is highly bound to human plasma proteins (>98%), predominantly to albumin.
Projected row 1236
- Medicine slug
- posaconazole
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 32
- Source count
- 24
- Agreement rate
- 0.958333
- Recorded readings
4 to 5 hours
- Numeric value
- 4
- Unit
- hours
- Source records
- 23
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 23 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5300d14-219d-4e1e-bfac-b413c40d6e3a (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
CL /F = Apparent total body clearance Healthy Volunteers 12 51618 (25) 2151 (25) 2764 (21) 1785 (29) 4 (3-6) 31 (40) 7.5 (26) Patients 50 37900 (42) 1580 (42) 2090 (38) 1310 (50) 4 (1.3-8.3) - 9.39 (45) Absorption When given orally in healthy volunteers, posaconazole delayed-release tablets are absorbed with a median T max of 4 to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4de6d839-e4bd-405c-83c5-8efc6abd0829 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
CL/F = Apparent total body clearance *300 mg twice daily on Day 1, then 300 mg once daily thereafter † Cav = time-averaged concentrations (i.e., AUC 0-24 hr /24hr) ‡ Median (minimum-maximum) Absorption: When given orally in healthy volunteers, posaconazole delayed-release tablets are absorbed with a median T max of 4 to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d14ceab-196e-4dc3-8b21-5c4629ada161 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
CL /F = Apparent total body clearance Healthy Volunteers 12 51618 (25) 2151 (25) 2764 (21) 1785 (29) 4 (3-6) 31 (40) 7.5 (26) Patients 50 37900 (42) 1580 (42) 2090 (38) 1310 (50) 4 (1.3-8.3) - 9.39 (45) Absorption When given orally in healthy volunteers, posaconazole delayed-release tablets are absorbed with a median T max of 4 to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b073b082-7b57-4423-8c06-4fd4263d6f84 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
-13,140] 31.7 (42) [12.4-67.3] Absorption: Absorption of Noxafil Delayed-Release Tablets When given orally in healthy volunteers, Noxafil delayed-release tablets are absorbed with a median T max of 4 to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:548124ce-8050-46a9-967b-ff23dfb18633 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
CL /F = Apparent total body clearance *300 mg twice daily on Day 1, then 300 mg once daily thereafter † Cav = time-averaged concentrations (i.e., AUC0-24 hr/24hr) ‡ Median (minimum-maximum) Absorption: When given orally in healthy volunteers, posaconazole delayed-release tablets are absorbed with a median T max of 4 to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e809a31a-09da-46bf-bcaa-f34b7f3b54a3 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
CL/F = Apparent total body clearance Absorption: When given orally in healthy volunteers, posaconazole delayed-release tablets are absorbed with a median T max of 4 to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f795eca-7a03-4c91-9a0e-c1235791b665 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
CL/F = Apparent total body clearance * 300 mg twice daily on Day 1, then 300 mg once daily thereafter † Cav = time-averaged concentrations (i.e., AUC 0-24 hr/24 hr ) ‡ Median (minimum-maximum) Absorption: Absorption of Posaconazole Delayed-Release Tablets When given orally in healthy volunteers, posaconazole delayed-release tablets are absorbed with a median T max of 4 to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9c81d88-8e2c-fa53-e053-6394a90ac5c4 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
CL/F = Apparent total body clearance *300 mg twice daily on Day 1, then 300 mg once daily thereafter † Cav = time-averaged concentrations (i.e., AUC 0-24 hr /24hr) ‡ Median (minimum-maximum) Absorption: Posaconazole Delayed-Release Tablets When given orally in healthy volunteers, posaconazole delayed-release tablets are absorbed with a median T max of 4 to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e1e69b8-cf41-47cc-a3ec-1baee55f099a (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
CL /F = Apparent total body clearance *300 mg twice daily on Day 1, then 300 mg once daily thereafter † Cav = time-averaged concentrations (i.e., AUC0-24 hr/24hr) ‡ Median (minimum-maximum) Absorption: When given orally in healthy volunteers, posaconazole delayed-release tablets are absorbed with a median T max of 4 to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:94a9b028-a2bc-4f41-884d-2d6c536881fc (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
CL/F = Apparent total body clearance * 300 mg twice daily on Day 1, then 300 mg once daily thereafter † Cav = time-averaged concentrations (i.e., AUC 0-24 hr /24hr) ‡ Median (minimum-maximum) Absorption: When given orally in healthy volunteers, posaconazole delayed-release tablets are absorbed with a median T max of 4 to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0bdf77ae-3639-49c1-b7c7-533f9d073084 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
CL/F = Apparent total body clearance * 300 mg twice daily on Day 1, then 300 mg once daily thereafter † Cav = time-averaged concentrations (i.e., AUC 0-24 hr/ 24hr) ‡ Median (minimum-maximum) Absorption: When given orally in healthy volunteers, posaconazole delayed-release tablets are absorbed with a median T max of 4 to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de95df83-a495-1900-e053-2995a90abf24 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
CL /F = Apparent total body clearance * 300 mg twice daily on Day 1, then 300 mg once daily thereafter † Cav = time-averaged concentrations (i.e., AUC 0-24 hr /24hr) ‡ Median (minimum-maximum) Absorption When given orally in healthy volunteers, posaconazole delayed-release tablets are absorbed with a median T max of 4 to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8a26673-261c-4e8e-b1e1-9e23aaf7f285 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
CL/F = Apparent total body clearance * 300 mg twice daily on Day 1, then 300 mg once daily thereafter † C av = time-averaged concentrations (i.e., AUC 0-24 hr/24hr) ‡ Median (minimum-maximum) Absorption: Absorption of Posaconazole Delayed-Release Tablets When given orally in healthy volunteers, posaconazole delayed-release tablets are absorbed with a median T max of 4 to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8412398b-c696-4f12-ba3a-da74dc8dadaf (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
CL/F = Apparent total body clearance Absorption: Absorption of Posaconazole Delayed-Release Tablets When given orally in healthy volunteers, posaconazole delayed-release tablets are absorbed with a median T max of 4 to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:573d89eb-05d8-4035-b406-6409f36ab707 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
CL/F = Apparent total body clearance *300 mg twice daily on Day 1, then 300 mg once daily thereafter † Cav = time-averaged concentrations (i.e., AUC 0-24 hr /24hr) ‡ Median (minimum-maximum) Absorption: When given orally in healthy volunteers, posaconazole delayed-release tablets are absorbed with a median T max of 4 to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42a53b61-be3b-4c69-a3df-d12401dbd0e4 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
CL /F = Apparent total body clearance Healthy Volunteers 12 51618 (25) 2151 (25) 2764 (21) 1785 (29) 4 (3-6) 31 (40) 7.5 (26) Patients 50 37900 (42) 1580 (42) 2090 (38) 1310 (50) 4 (1.3-8.3) - 9.39 (45) Absorption When given orally in healthy volunteers, posaconazole delayed-release tablets are absorbed with a median T max of 4 to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0e8023a-3c82-e455-a57b-ccc0206ad156 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
aged concentrations (i.e., AUC 0-24 hr /24hr) ‡ Median (minimum-maximum) Absorption: When given orally in healthy volunteers, posaconazole delayed-release tablets are absorbed with a median Tmax of 4 to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e883b495-d7e7-6d58-e053-2a95a90a1cd3 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
CL/F = Apparent total body clearance Absorption: When given orally in healthy volunteers, posaconazole delayed-release tablets are absorbed with a median T max of 4 to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f15fc7d4-04ea-4be5-bfed-9a8bae74591c (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
CL /F = Apparent total body clearance Healthy Volunteers 12 51618 (25) 2151 (25) 2764 (21) 1785 (29) 4 (3-6) 31 (40) 7.5 (26) Patients 50 37900 (42) 1580 (42) 2090 (38) 1310 (50) 4 (1.3-8.3) - 9.39 (45) Absorption When given orally in healthy volunteers, posaconazole delayed-release tablets are absorbed with a median T max of 4 to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e031b632-8e57-4359-87bd-a5da02bdc55f (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
(n=23) 723 (86) [6.70-2256] 9093 (80) [1564-26,794] 76.1 (78) [14.9-256] 3088 (84) [407-13,140] 31.7 (42) [12.4-67.3] Absorption: Absorption of Posaconazole Delayed-Release Tablets When given orally in healthy volunteers, Noxafil delayed-release tablets are absorbed with a median T max of 4 to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dfbc636f-d8a7-4232-a6b0-cda49caadc9b (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
CL /F = Apparent total body clearance * 300 mg BID on Day 1, then 300 mg QD thereafter † Cav = time-averaged concentrations (i.e., AUC0-24 hr/24hr) ‡ Median (minimum-maximum) Absorption: When given orally in healthy volunteers, posaconazole delayed-release tablets are absorbed with a median T max of 4 to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8d8dd03-46b5-bd26-bb27-7ca31d8c3326 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
CL /F = Apparent total body clearance * 300 mg twice daily on Day 1, then 300 mg once daily thereafter † Cav = time-averaged concentrations (i.e., AUC 0-24 hr /24hr) ‡ Median (minimum-maximum) Absorption : Absorption of Posaconazole Delayed-Release Tablets When given orally in healthy volunteers, posaconazole delayed-release tablets are absorbed with a median T max of 4 to 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d2daba09-f1c2-4764-a567-1291be4892b9 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
CL /F = Apparent total body clearance Healthy Volunteers 12 51618 (25) 2151 (25) 2764 (21) 1785 (29) 4 (3-6) 31 (40) 7.5 (26) Patients 50 37900 (42) 1580 (42) 2090 (38) 1310 (50) 4 (1.3-8.3) - 9.39 (45) Absorption When given orally in healthy volunteers, posaconazole delayed-release tablets are absorbed with a median T max of 4 to 5 hours.
36 hrs
- Numeric value
- 36
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:282ddea7-47d8-44e4-8806-169d7cafa951 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
(hr) AUC (I) (ng∙hr/mL) CL/F (L/hr) t ½ (hr) 200 mg fasted (n=20) n=15 for AUC (I), CL/F, and t 1/2 132 (50) [45 to 267] 3.50 [1.5 to 36 The subject with T max of 36 hrs had relatively constant plasma levels over 36 hrs (1.7 ng/mL difference between 4 hrs and 36 hrs). ] 4179 (31) [2,705 to 7,269] 51 (25) [28 to 74] 23.5 (25) [15.3 to 33.7] 200 mg nonfat (n=20) 378 (43) [131 to 834] 4 [3 to 5] 10,7
Projected row 1237
- Medicine slug
- posaconazole
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 32
- Source count
- 29
- Agreement rate
- 1
- Recorded readings
261 L
- Numeric value
- 261
- Unit
- L
- Source records
- 29
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 29 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c551e121-d5fc-4b35-ba9f-72ce3a314fdc (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
T max = time of observed maximum plasma concentration. * 300 mg dose administered over 90 minutes once a day following twice daily dosing on Day 1 † Median (minimum-maximum) Distribution: The mean volume of distribution of posaconazole after intravenous solution administration was 261 L and ranged from 226 to 295 L between studies and dose levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5300d14-219d-4e1e-bfac-b413c40d6e3a (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
n ® ) (Increase in gastric motility) 15 mg four times daily for 2 days (Day -1 and 1) ↓14% (0.86, 0.73,1.02) ↓7% (0.93, 0.803,1.07) Distribution: The mean volume of distribution of posaconazole after intravenous solution administration was 261 L and ranged from 226-295 L between studies and dose levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4de6d839-e4bd-405c-83c5-8efc6abd0829 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Distribution: The mean volume of distribution of posaconazole after intravenous solution administration was 261 L and ranged from 226 to 295 L between studies and dose levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86be8cdb-c991-4754-b8f4-1ab79ac40bda (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
(ng/mL) T max † (hr) AUC 0-24 (ng*hr/mL) Cav (ng/mL) C min (ng/mL) 10/14 49 3280 (74) 1.5 (0.98-4.0) 36100 (35) 1500 (35) 1090 (44) Distribution: The mean volume of distribution of posaconazole after intravenous solution administration was 261 L and ranged from 226-295 L between studies and dose levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d14ceab-196e-4dc3-8b21-5c4629ada161 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
n ® ) (Increase in gastric motility) 15 mg four times daily for 2 days (Day -1 and 1) ↓14% (0.86, 0.73,1.02) ↓7% (0.93, 0.803,1.07) Distribution: The mean volume of distribution of posaconazole after intravenous solution administration was 261 L and ranged from 226-295 L between studies and dose levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91f89a3b-2479-4d05-9997-7b0cfaa496ec (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
T max = time of observed maximum plasma concentration. * 300 mg dose administered over 90 minutes once a day following twice daily dosing on Day 1 † Median (minimum-maximum) Distribution: The mean volume of distribution of posaconazole after intravenous solution administration was 261 L and ranged from 226-295 L between studies and dose levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b073b082-7b57-4423-8c06-4fd4263d6f84 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
er orally with BOOST or via an NG tube with BOOST (n=16) Via NG tube NG = nasogastric ↓19% (0.81; 0.71-0.91) ↓23% (0.77; 0.69-0.86) Distribution: The mean volume of distribution of posaconazole after intravenous solution administration was 261 L and ranged from 226-295 L between studies and dose levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e809a31a-09da-46bf-bcaa-f34b7f3b54a3 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
n ® ) (Increase in gastric motility) 15 mg four times daily for 2 days (Day -1 and 1) ↓14% (0.86, 0.73,1.02) ↓7% (0.93, 0.803,1.07) Distribution: The mean volume of distribution of posaconazole after intravenous solution administration was 261 L and ranged from 226 to 295 L between studies and dose levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f795eca-7a03-4c91-9a0e-c1235791b665 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
CI=Confidence interval * 48.5 g fat † Median (Min, Max) reported for T max Distribution: The mean volume of distribution of posaconazole after intravenous solution administration was 261 L and ranged from 226 to 295 L between studies and dose levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9c81d88-8e2c-fa53-e053-6394a90ac5c4 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Distribution: The mean volume of distribution of posaconazole after intravenous solution administration was 261 L and ranged from 226 to 295 L between studies and dose levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2ba0343-cd17-4b23-8356-005a1dfd0b35 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
T max = time of observed maximum plasma concentration. * 300 mg dose administered over 90 minutes once a day following twice daily dosing on Day 1 † Median (minimum-maximum) Distribution: The mean volume of distribution of posaconazole after intravenous solution administration was 261 L and ranged from 226-295 L between studies and dose levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52d9d29e-4a37-4926-aa57-8477f5447b34 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
T max = time of observed maximum plasma concentration. * 300 mg dose administered over 90 minutes once a day following twice daily dosing on Day 1 † Median (minimum-maximum) Distribution : The mean volume of distribution of posaconazole after intravenous solution administration was 261 L and ranged from 226 to 295 L between studies and dose levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:94a9b028-a2bc-4f41-884d-2d6c536881fc (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Distribution: The mean volume of distribution of posaconazole after intravenous solution administration was 261 L and ranged from 226 to 295 L between studies and dose levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0bdf77ae-3639-49c1-b7c7-533f9d073084 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Distribution: The mean volume of distribution of posaconazole after intravenous solution administration was 261 L and ranged from 226 to 295 L between studies and dose levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de95df83-a495-1900-e053-2995a90abf24 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Distribution: The mean volume of distribution of posaconazole after intravenous solution administration was 261 L and ranged from 226 to 295 L between studies and dose levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8a26673-261c-4e8e-b1e1-9e23aaf7f285 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
CI=Confidence interval * 48.5 g fat † Median (Min, Max) reported for T max Distribution: The mean volume of distribution of posaconazole after intravenous solution administration was 261 L and ranged from 226 to 295 L between studies and dose levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8412398b-c696-4f12-ba3a-da74dc8dadaf (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
CI=Confidence interval Distribution: The mean volume of distribution of posaconazole after intravenous solution administration was 261 L and ranged from 226-295 L between studies and dose levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e88e379-b712-4dec-97a2-c90ef3638372 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
T max = time of observed maximum plasma concentration. * 300 mg dose administered over 90 minutes once a day following twice daily dosing on Day 1 † Median (minimum-maximum) Distribution: The mean volume of distribution of posaconazole after intravenous solution administration was 261 L and ranged from 226 to 295 L between studies and dose levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:573d89eb-05d8-4035-b406-6409f36ab707 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Distribution: The mean volume of distribution of posaconazole after intravenous solution administration was 261 L and ranged from 226 to 295 L between studies and dose levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42a53b61-be3b-4c69-a3df-d12401dbd0e4 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
n ® ) (Increase in gastric motility) 15 mg four times daily for 2 days (Day -1 and 1) ↓14% (0.86, 0.73,1.02) ↓7% (0.93, 0.803,1.07) Distribution: The mean volume of distribution of posaconazole after intravenous solution administration was 261 L and ranged from 226-295 L between studies and dose levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:282ddea7-47d8-44e4-8806-169d7cafa951 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
lly with BOOST or via an NG tube with BOOST (n=16) Via NG tube NG = nasogastric ↓19% (0.81; 0.71 to 0.91) ↓23% (0.77; 0.69 to 0.86) Distribution: The mean volume of distribution of posaconazole after intravenous solution administration was 261 L and ranged from 226 to 295 L between studies and dose levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ebbd88b-547b-4b49-ab73-98094a2d5a79 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Day N C max (ng/mL) T max Median (minimum-maximum) (hr) AUC 0-24 (ng * hr/mL) C av (ng/mL) C min (ng/mL) 10/14 49 3280 (74) 1.5 (0.98-4.0) 36100 (35) 1500 (35) 1090 (44) Distribution The mean volume of distribution of posaconazole after intravenous solution administration was 261 L and ranged from 226-295 L between studies and dose levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0e8023a-3c82-e455-a57b-ccc0206ad156 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Distribution: The mean volume of distribution of posaconazole after intravenous solution administration was 261 L and ranged from 226 to 295 L between studies and dose levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e883b495-d7e7-6d58-e053-2a95a90a1cd3 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
n ® ) (Increase in gastric motility) 15 mg four times daily for 2 days (Day -1 and 1) ↓14% (0.86, 0.73,1.02) ↓7% (0.93, 0.803,1.07) Distribution: The mean volume of distribution of posaconazole after intravenous solution administration was 261 L and ranged from 226-295 L between studies and dose levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f15fc7d4-04ea-4be5-bfed-9a8bae74591c (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
n ® ) (Increase in gastric motility) 15 mg four times daily for 2 days (Day -1 and 1) ↓14% (0.86, 0.73,1.02) ↓7% (0.93, 0.803,1.07) Distribution: The mean volume of distribution of posaconazole after intravenous solution administration was 261 L and ranged from 226-295 L between studies and dose levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dfbc636f-d8a7-4232-a6b0-cda49caadc9b (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
Distribution: The mean volume of distribution of posaconazole after intravenous solution administration was 261 L and ranged from 226 to 295 L between studies and dose levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8d8dd03-46b5-bd26-bb27-7ca31d8c3326 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
CI=Confidence interval * 48.5 grams fat † Median (Min, Max) reported for T max Distribution: The mean volume of distribution of posaconazole after intravenous solution administration was 261 L and ranged from 226 to 295 L between studies and dose levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4032672e-1bb0-427d-a3b3-09cda4beaf34 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
T max = time of observed maximum plasma concentration. * 300 mg dose administered over 90 minutes once a day following twice daily dosing on Day 1 † Median (minimum-maximum) Distribution: The mean volume of distribution of posaconazole after intravenous solution administration was 261 L and ranged from 226-295 L between studies and dose levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d2daba09-f1c2-4764-a567-1291be4892b9 (opens source in a new tab)
Posaconazole label
Version not recorded · Effective date not recorded
n ® ) (Increase in gastric motility) 15 mg four times daily for 2 days (Day -1 and 1) ↓14% (0.86, 0.73,1.02) ↓7% (0.93, 0.803,1.07) Distribution: The mean volume of distribution of posaconazole after intravenous solution administration was 261 L and ranged from 226-295 L between studies and dose levels.
Projected row 1238
- Medicine slug
- pralatrexate
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
12-18 hours
- Numeric value
- 12
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5daa583-4965-4564-ad87-41ffe6c08a11 (opens source in a new tab)
Pralatrexate label
Version not recorded · Effective date not recorded
The terminal elimination half-life of pralatrexate was 12-18 hours (coefficient of variance [CV] = 62-120%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f3d9c4d-9386-4451-b712-0fbdc5478d8f (opens source in a new tab)
Pralatrexate label
Version not recorded · Effective date not recorded
The terminal elimination half-life of pralatrexate was 12-18 hours (coefficient of variance [CV] = 62-120%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc3df863-c51c-49c5-283a-d6808fb49258 (opens source in a new tab)
Pralatrexate label
Version not recorded · Effective date not recorded
The terminal elimination half-life of pralatrexate was 12-18 hours (coefficient of variance [CV] = 62-120%).
Projected row 1239
- Medicine slug
- pralatrexate
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
67%
- Numeric value
- 67
- Unit
- %
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5daa583-4965-4564-ad87-41ffe6c08a11 (opens source in a new tab)
Pralatrexate label
Version not recorded · Effective date not recorded
Protein binding of pralatrexate is approximately 67% in vitro.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f3d9c4d-9386-4451-b712-0fbdc5478d8f (opens source in a new tab)
Pralatrexate label
Version not recorded · Effective date not recorded
Protein binding of pralatrexate is approximately 67% in vitro.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc3df863-c51c-49c5-283a-d6808fb49258 (opens source in a new tab)
Pralatrexate label
Version not recorded · Effective date not recorded
Protein binding of pralatrexate is approximately 67% in vitro.
Projected row 1240
- Medicine slug
- pralatrexate
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
105 L
- Numeric value
- 105
- Unit
- L
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5daa583-4965-4564-ad87-41ffe6c08a11 (opens source in a new tab)
Pralatrexate label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of pralatrexate S- and R-diastereomers is 105 L and 37 L, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f3d9c4d-9386-4451-b712-0fbdc5478d8f (opens source in a new tab)
Pralatrexate label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of pralatrexate S- and R-diastereomers is 105 L and 37 L, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc3df863-c51c-49c5-283a-d6808fb49258 (opens source in a new tab)
Pralatrexate label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of pralatrexate S- and R-diastereomers is 105 L and 37 L, respectively.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=1230Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.